8-K: Arvinas ARV-102 Phase 1 Data Shows Strong LRRK2 Degradation

Arvinas, Inc. announced positive Phase 1 clinical trial data for ARV-102, demonstrating over 50% LRRK2 degradation in Parkinson's disease patients and plans for further neurodegenerative disease trials.

Summary

• Positive Phase 1 clinical trial data for ARV-102, an investigational PROTAC degrader, in patients with Parkinson's disease.
• ARV-102 achieved approximately 50% or greater LRRK2 degradation in the cerebrospinal fluid (CSF) of patients treated for 28 days.
• The drug was well tolerated across all dose levels (20 mg, 40 mg, or 80 mg once daily for 28 days) with no serious adverse events, discontinuations, or deaths reported.
• ARV-102 demonstrated brain penetration, with CSF levels increasing in a dose-dependent manner.
• Reduction of endolysosomal and neuroinflammatory pathway proteins (e.g., CD68, GPNMB) elevated in LRRK2-related Parkinson's disease was observed.
• Plans to continue investigation of ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction.
• Intends to initiate a Phase 1b clinical trial in progressive supranuclear palsy (PSP) in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, given the strong efficacy data (LRRK2 degradation) and excellent safety profile in a challenging therapeutic area, positioning ARV-102 for further advanced clinical trials.

Positives

• ARV-102 achieved approximately 50% or greater LRRK2 degradation in CSF at all doses by day 14 and maintained the reduction through day 28.
• The drug was well tolerated in participants with Parkinson's disease, with all treatment-emergent and treatment-related adverse events being mild in severity.
• No serious adverse events, discontinuations, or deaths were reported during the trial.
• No significant changes in lung functions or respiratory symptoms were observed during the 28 days of treatment or during follow-up.
• ARV-102 levels in CSF increased in a dose-dependent manner after multiple doses, indicating brain penetration.
• Reduction of endolysosomal and neuroinflammatory pathway proteins (e.g., CD68, GPNMB) that are elevated in LRRK2-related Parkinson's disease was observed.
• Pharmacology and changes in peripheral biomarkers in patients with Parkinson's disease were consistent with observations in healthy volunteers.

Risks

• Actual results or events could differ materially from the plans, intentions, and expectations disclosed in forward-looking statements.
• Risks and uncertainties include whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, on its current timelines or at all.
• Risks related to clinical trial results and the interpretation thereof, including with respect to ARV-102.
• Arvinas's ability to protect its intellectual property portfolio.
• Arvinas's reliance on third parties.
• Whether Arvinas will be able to raise capital when needed.
• Whether Arvinas's cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• Other important factors discussed in the Risk Factors section of Arvinas's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent other reports filed with the U.S. Securities and Exchange Commission.

Future Outlook

Arvinas plans to continue investigating ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction. Pending regulatory feedback, the company intends to initiate a Phase 1b clinical trial in progressive supranuclear palsy (PSP) in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while continuing to evaluate development options for ARV-102 in Parkinson's disease.

Management Comments

• "These data represent exciting progress in the Parkinson's disease treatment landscape. Importantly, ARV-102's reduction of LRRK2 protein levels and other key biomarkers in patients with Parkinson's disease suggests that PROTACs may offer a path for future treatment approaches. I look forward to following the continued advancement of ARV-102 and what it could bring for patients." Andrew Siderowf, M.D., Chair of the Parkinson Study Group.
• "We are pleased to see compelling and consistent data that reinforce the continued development of ARV-102 as a potential treatment for neurodegenerative diseases like Parkinson's disease and progressive supranuclear palsy that profoundly impact millions of patients and their families worldwide. To our knowledge, this level of biomarker modulation has not previously been demonstrated by LRRK2 inhibitors, and we believe these data serve as the first of its kind." Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Arvinas.
• "There is strong evidence that lysosomal dysfunction driven by increased LRRK2 in patients with PSP leads to significant declines in function over one year." Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Arvinas.

Industry Context

StockSavvy.ai notes that these positive Phase 1 results for ARV-102 reinforce the growing potential of PROTAC (PROteolysis TArgeting Chimera) technology in addressing challenging neurodegenerative diseases. The ability to achieve significant LRRK2 degradation in CSF, coupled with a favorable safety profile, positions Arvinas as a leader in developing novel therapeutic approaches for conditions like Parkinson's disease and progressive supranuclear palsy, where current treatments are limited. This advancement could differentiate Arvinas from traditional small molecule inhibitors by offering a potentially more effective mechanism of action through targeted protein degradation.

Comparison to Industry Standards

• Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Arvinas, stated that "this level of biomarker modulation has not previously been demonstrated by LRRK2 inhibitors, and we believe these data serve as the first of its kind." This suggests ARV-102's performance in LRRK2 degradation in CSF is potentially superior or unique compared to other LRRK2 inhibitors in development or previously tested.
• The company targeted a 50% LRRK2 reduction based on data showing that patients with Parkinson's disease have a two-fold elevation of LRRK2, indicating a strategic and data-driven approach to clinical success metrics.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data, potentially increasing company valuation and future revenue prospects.
• Patients (Parkinson's Disease, PSP): Potential for a new, effective treatment option for debilitating neurodegenerative diseases with high unmet medical need.
• Employees: Positive impact on morale and job security due to successful drug development.
• Regulatory Authorities: Will be closely monitoring further trial results and regulatory submissions.

Next Steps

• Continue investigation of ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction.
• Initiate a Phase 1b clinical trial in progressive supranuclear palsy (PSP) in the second quarter of 2026, pending regulatory feedback.
• Potentially initiate a registrational trial in late 2026.
• Continue to evaluate development options for ARV-102 in Parkinson's disease.

Key Dates

Recommendation

The positive Phase 1 data for ARV-102, demonstrating significant LRRK2 degradation and an excellent safety profile, represents a major de-risking event for Arvinas's pipeline. The ability to achieve over 50% LRRK2 degradation in CSF, coupled with plans for a Phase 1b trial in PSP and potential registrational trial initiation in late 2026, indicates strong progress towards addressing high unmet medical needs in neurodegenerative diseases. This breakthrough in PROTAC technology for CNS disorders, with management claiming "first of its kind" biomarker modulation, suggests substantial future value creation and warrants a strong buy recommendation for long-term investors.

Keywords

Arvinas, ARVN, ARV-102, PROTAC, Parkinson's disease, LRRK2, neurodegenerative diseases, progressive supranuclear palsy, PSP, clinical trial, Phase 1, biotechnology, protein degradation, CNS, neurology